Document is current
Any future updates will be listed below
-
Authors
Marks, Adam
Siu, Sophia https://orcid.org/0000-0002-1966-0100
Bianchini, Filippo https://orcid.org/0000-0002-0746-7629
Wang, Chunxi
Lakshmi, Ashwitha
Phelan, Matthew
Zhu, Andrew https://orcid.org/0009-0005-3089-7634
Moon, Chang
Morla-Folch, Judit
Teunissen, Abraham J. P.
Amabile, Angelo
Baccarini, Alessia
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Brody, Joshua D. https://orcid.org/0000-0002-0850-6730
Dong, Yizhou https://orcid.org/0000-0001-5786-0659
Brown, Brian D. https://orcid.org/0000-0002-3670-8778
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01DK138025)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA257195)
U.S. Department of Health & Human Services | National Institutes of Health (T33AI078892)
U.S. Department of Health & Human Services | National Institutes of Health (F30AI194739)
U.S. Department of Health & Human Services | National Institutes of Health (U01EB035521)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- License Information
-
More Information
Article History
Received: 16 November 2024
Accepted: 20 March 2026
First Online: 29 April 2026
Competing interests
: B.D.B. has a patent on the use of miRTs in gene vectors, which is not related to this work. B.D.B. is on the scientific advisory boards of Asgard Therapeutics, Noetik and Navexio and consults for Merck. Y.D. is a cofounder and holds equity in Immunanoengineering Therapeutics. The other authors declare no competing interests.
